Literature DB >> 1863402

Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group.

D C Montefiori1, L B Lefkowitz, R E Keller, V Holmberg, E Sandstrom, J P Phair.   

Abstract

Neutralizing and complement-mediated infection-enhancing antibodies to HIV-1 were measured in sera or plasma from 54 HIV-1-positive individuals at various stages of disease, and from an additional 36 HIV-1-positive individuals for whom no clinical data were available. Antibodies were measured in microtiter infection assays utilizing MT-2 cells and the IIIB strain of HIV-1. The frequency of detection of both types of antibodies was identical, being 77 out of 90 cases (86%). Neutralizing and infection-enhancing antibodies were not always found together, and in four cases both were undetectable. No correlation was found between titers of either type of antibody and stage of disease. Furthermore, titers of infection-enhancing antibodies at early stages of disease did not predict rate of disease progression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1863402     DOI: 10.1097/00002030-199105000-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

Review 1.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

Review 2.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

3.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

4.  Role of Complement and Antibodies in the Control and Facilitation of HIV Disease.

Authors:  Zoltán Prohászka; Ferenc D Tóth; Dénes Bánhegyi; George Füst
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

6.  Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  D C Montefiori; B S Graham; S Kliks; P F Wright
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

7.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen.

Authors:  M J McElrath; L Corey; P D Greenberg; T J Matthews; D C Montefiori; L Rowen; L Hood; J I Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

9.  B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells.

Authors:  S Moir; A Malaspina; Y Li; T W Chun; T Lowe; J Adelsberger; M Baseler; L A Ehler; S Liu; R T Davey; J A Mican; A S Fauci
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

10.  Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity.

Authors:  L M Huang; A Joshi; R Willey; J Orenstein; K T Jeang
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.